
PVLA Stock Forecast & Price Target
PVLA Analyst Ratings
Bulls say
Palvella Therapeutics is positioned for success with their innovative platform and experienced management team, leading to potential growth in the rare genetic skin disease market. However, there are risks and limitations to consider as the company works towards their NDA submission and potential future revenue targets.
Bears say
Palvella Therapeutics is a clinical-stage biopharmaceutical company focusing on the development and commercialization of novel therapies for rare skin diseases, which currently has one product candidate, QTORIN, in clinical trials. However, the company's clinical development process is lengthy and costly with a high risk of delays, added costs, or failure to complete. Additionally, its lead candidate, QTORIN, has shown mixed results in clinical trials and relies on a novel and unproven technology, which may hinder its adoption and reduce approval prospects for other QTORIN-based candidates. There is also a risk that the company's patents may be challenged.
This aggregate rating is based on analysts' research of Palvella Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PVLA Analyst Forecast & Price Prediction
Start investing in PVLA
Order type
Buy in
Order amount
Est. shares
0 shares